Early versus Late Antipseudomonal β-Lactam Antibiotic Dose Adjustment in Critically Ill Sepsis Patients with Acute Kidney Injury: A Prospective Observational Cohort Study

Namareq F Aldardeer,Maram M Alshreef,Emad A Alharbi,Ahmad K Aljabri,Mohammad H Aljawadi,Thamer A Almangour,Saad Alobaili,Mohammed I Alarifi,Awad Alomari,Abdullah M Alhammad,Mohammad Aljawadi,Mohammed Alarifi
DOI: https://doi.org/10.1093/ofid/ofae059
2024-02-01
Open Forum Infectious Diseases
Abstract:Abstract Background Acute kidney injury (AKI) is a common complication of sepsis, contributing to an increased mortality rate. However, some studies have demonstrated that renal function improves in sepsis patients with AKI within 48 hours, raising questions about the necessity for early antibiotic adjustment. This study evaluates the association between the timing of β-lactam antipseudomonal dose adjustment and the outcomes of critically ill sepsis patients with AKI. Methods A prospective, multicenter observational study of critically ill patients aged ≥ 18 years admitted to the intensive care unit (ICU) with sepsis and AKI and started on antipseudomonal β-lactam therapy. After the initial dose, eligible patients were grouped as early β-lactam antibiotic (E-BLA) or late β-lactam antibiotic (L-BLA) dose adjustments based on the administration of subsequent renally adjusted doses within 24 hours and after 24 hours of sepsis recognition, respectively. The main outcome of interest was in-hospital mortality. Results Among 1185 patients screened, 224 (mean age, 62.7 ± 16.8 years; 62% males) met inclusion criteria. Eighty-four and 140 patients were included in the E-BLA and L-BLA groups, respectively. Approximately half of the cohort presented with AKI stage II, and piperacillin/tazobactam was prescribed as initial empirical therapy in more than 50% of the cohort. In the multivariable Cox proportional hazards model, L-BLA was associated with a significant reduction in in-hospital mortality compared to E-BLA (HR = 0.588, 95% CI = 0.355–0.974). Conclusions In sepsis patients with AKI, L-BLA was associated with in-hospital mortality benefits.
immunology,infectious diseases,microbiology
What problem does this paper attempt to address?